{"id":"https://openalex.org/W4297937716","doi":null,"title":"a C-terminal cyclic 8-13 neurotensin fragment analog appears less exposed to neprilysin when it crosses the blood brain barrier than the cerebrospinal fluid brain barrier in mice","display_name":"a C-terminal cyclic 8-13 neurotensin fragment analog appears less exposed to neprilysin when it crosses the blood brain barrier than the cerebrospinal fluid brain barrier in mice","publication_year":1996,"publication_date":"1996-01-01","ids":{"openalex":"https://openalex.org/W4297937716"},"language":"en","primary_location":{"id":"pmh:oai:HAL:hal-00357437v1","doi":null,"is_oa":false,"landing_page_url":"https://hal.science/hal-00357437","pdf_url":null,"source":{"id":"https://openalex.org/S4306402512","display_name":"HAL","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4405252976","host_organization_name":"Centre pour la Communication Scientifique Directe","host_organization_lineage":["https://openalex.org/I4405252976"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Neuroscience Letters, 1996, 217 (1), pp.58-60","raw_type":"info:eu-repo/semantics/article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5053535902","display_name":"Fm van Kemmel","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"van Kemmel, Fm","raw_affiliation_strings":["Unit\u00e9 de neuropsychopharmacologie experimentale"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Unit\u00e9 de neuropsychopharmacologie experimentale","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018177329","display_name":"Isabelle Dubuc","orcid":"https://orcid.org/0000-0003-3432-1980","observed_orcids":["https://orcid.org/0000-0003-3432-1980"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dubuc, Isabelle","raw_affiliation_strings":["Unit\u00e9 de neuropsychopharmacologie experimentale"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Unit\u00e9 de neuropsychopharmacologie experimentale","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020102083","display_name":"Elisabeth Bourdel","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bourdel, Elisabeth","raw_affiliation_strings":["Laboratoire des Amino-acides Peptides et Prot\u00e9ines"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Laboratoire des Amino-acides Peptides et Prot\u00e9ines","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064733011","display_name":"Jean\u2010Alain Fehrentz","orcid":"https://orcid.org/0000-0002-6064-3118","observed_orcids":["https://orcid.org/0000-0002-6064-3118"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Fehrentz, Jean-Alain","raw_affiliation_strings":["Laboratoire des Amino-acides Peptides et Prot\u00e9ines"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Laboratoire des Amino-acides Peptides et Prot\u00e9ines","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052978566","display_name":"Jean Mart\u00ednez","orcid":"https://orcid.org/0000-0002-9267-4621","observed_orcids":["https://orcid.org/0000-0002-9267-4621","https://orcid.org/0000-0002-4551-4254"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Martinez, Jean","raw_affiliation_strings":["Laboratoire des Amino-acides Peptides et Prot\u00e9ines"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Laboratoire des Amino-acides Peptides et Prot\u00e9ines","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5047845437","display_name":"Jean Constentin","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Constentin, Jean","raw_affiliation_strings":["Unit\u00e9 de neuropsychopharmacologie experimentale"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Unit\u00e9 de neuropsychopharmacologie experimentale","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.45768948,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"217","issue":"1","first_page":"58","last_page":"60"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11872","display_name":"Barrier Structure and Function Studies","score":0.7836999893188477,"subfield":{"id":"https://openalex.org/subfields/2808","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11872","display_name":"Barrier Structure and Function Studies","score":0.7836999893188477,"subfield":{"id":"https://openalex.org/subfields/2808","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10814","display_name":"Neuropeptides and Animal Physiology","score":0.13109999895095825,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.006200000178068876,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/neurotensin","display_name":"neurotensin","score":0.968999981880188},{"id":"https://openalex.org/keywords/neprilysin","display_name":"neprilysin","score":0.9309999942779541},{"id":"https://openalex.org/keywords/blood-brain-barrier","display_name":"blood-brain barrier","score":0.8600000143051147},{"id":"https://openalex.org/keywords/cerebrospinal-fluid","display_name":"cerebrospinal fluid","score":0.9539999961853027},{"id":"https://openalex.org/keywords/peptide-degradation","display_name":"peptide degradation","score":0.44600000977516174},{"id":"https://openalex.org/keywords/neurotensin-analogs","display_name":"neurotensin analogs","score":0.6850000023841858},{"id":"https://openalex.org/keywords/mice","display_name":"mice","score":0.41200000047683716}],"concepts":[{"id":"https://openalex.org/C2778976297","wikidata":"https://www.wikidata.org/wiki/Q419576","display_name":"Neurotensin","level":4,"score":0.8286299705505371},{"id":"https://openalex.org/C104826730","wikidata":"https://www.wikidata.org/wiki/Q414232","display_name":"Neprilysin","level":3,"score":0.7923073768615723},{"id":"https://openalex.org/C2779651940","wikidata":"https://www.wikidata.org/wiki/Q54196","display_name":"Cerebrospinal fluid","level":2,"score":0.7394635677337646},{"id":"https://openalex.org/C2778402981","wikidata":"https://www.wikidata.org/wiki/Q221694","display_name":"Blood\u2013brain barrier","level":3,"score":0.6932499408721924},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.45598816871643066},{"id":"https://openalex.org/C2779664074","wikidata":"https://www.wikidata.org/wiki/Q3518405","display_name":"Terminal (telecommunication)","level":2,"score":0.45325595140457153},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3927461504936218},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.35443419218063354},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3097744584083557},{"id":"https://openalex.org/C118303440","wikidata":"https://www.wikidata.org/wiki/Q419968","display_name":"Neuropeptide","level":3,"score":0.3033372759819031},{"id":"https://openalex.org/C529278444","wikidata":"https://www.wikidata.org/wiki/Q47273","display_name":"Central nervous system","level":2,"score":0.19561895728111267},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.1936836838722229},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.1475975513458252},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.12281233072280884},{"id":"https://openalex.org/C127413603","wikidata":"https://www.wikidata.org/wiki/Q11023","display_name":"Engineering","level":0,"score":0.0795668363571167},{"id":"https://openalex.org/C76155785","wikidata":"https://www.wikidata.org/wiki/Q418","display_name":"Telecommunications","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"pmh:oai:HAL:hal-00357437v1","doi":null,"is_oa":false,"landing_page_url":"https://hal.science/hal-00357437","pdf_url":null,"source":{"id":"https://openalex.org/S4306402512","display_name":"HAL","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4405252976","host_organization_name":"Centre pour la Communication Scientifique Directe","host_organization_lineage":["https://openalex.org/I4405252976"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Neuroscience Letters, 1996, 217 (1), pp.58-60","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9074000120162964,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2040734168","https://openalex.org/W2023782137","https://openalex.org/W2013221494","https://openalex.org/W1987987383","https://openalex.org/W2020908803","https://openalex.org/W1975250189","https://openalex.org/W1995070407","https://openalex.org/W2074050589","https://openalex.org/W2079685938","https://openalex.org/W2168153088"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-11-08T12:12:28.789561","created_date":"2022-10-01T00:00:00"}